Iraj Ghaini Hesaroieh
Family · Lilburn, GANPI 1316644560
Payments from drug & device makers
Across 78 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$212
- Boehringer Ingelheim$201
- GSK$142
- Amgen$120
- Pfizer$111
- Shield Therapeutics Inc$96
- plus $505 from 14 others
What the payments were for
- Food & beverage$1,386100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $212 |
| Boehringer Ingelheim | 10 | $201 |
| GSK | 8 | $142 |
| Amgen | 8 | $120 |
| Pfizer | 6 | $111 |
| Shield Therapeutics Inc | 5 | $96 |
| Lilly USA, LLC | 5 | $85 |
| Exact Sciences | 4 | $72 |
| Xeris Pharmaceuticals, Inc. | 3 | $55 |
| Astellas Pharma US Inc | 2 | $44 |
| Merck | 2 | $36 |
| Novo Nordisk | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Sanofi Pasteur Inc. | 1 | $28 |
| Corcept Therapeutics | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $19 |
| Abbott | 1 | $17 |
| Cequr Corporation | 1 | $11 |
How this compares
$1,386 in reported general payments places this provider in the 70th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 35 | $45,457 |
| OzempicSemaglutide | 19 | $24,133 |
| JanuviaSitagliptin Phosphate | 16 | $23,260 |
| JardianceEmpagliflozin | 14 | $22,782 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $16,093 |
| MyrbetriqMirabegron | 12 | $11,524 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $6,641 |
| Atorvastatin Calcium | 224 | $1,886 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 64 | $1,685 |
| Gabapentin | 62 | $1,202 |
| Memantine Hcl | 24 | $1,184 |
| Levothyroxine Sodium | 94 | $951 |
| Levetiracetam | 16 | $759 |
| Amlodipine Besylate | 132 | $636 |
| Diclofenac Sodium | 28 | $568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $212 | $45,45735 claims |
| Novo NordiskOzempic | $34 | $24,13319 claims |
| MerckJanuvia | $36 | $23,26016 claims |
| Boehringer IngelheimJardiance | $201 | $22,78214 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $142 | $22,73432 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $11,52412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,258 family providers in Georgia.
Other family in Lilburn
- Anna Carolina WrightLilburn$69K
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.